Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Disorders of Leukocytes01:27

Disorders of Leukocytes

997
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
997
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

370
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
370
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.3K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.3K
Lineage Commitment01:21

Lineage Commitment

3.0K
Commitment is the  process whereby stem cells:
3.0K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Durable response to salvage gilteritinib, allogeneic stem cell rescue and maintenance therapy in relapsed AML with a <i>FLT3</i> N676K variant.

Leukemia & lymphoma·2026
Same author

Real-world, multi-omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS).

HemaSphere·2026
Same author

ELN-DAVID Recommendations for NGS-based FLT3-ITD MRD Testing in Patients with Acute Myeloid Leukemia.

Blood·2026
Same author

Olutasidenib as maintenance therapy after treatment response in acute myeloid leukemia with persistent <i>IDH1</i> mutation.

Blood neoplasia·2026
Same author

Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.

Blood advances·2026

関連する実験動画

Updated: Aug 2, 2025

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.1K

急性骨髄性白血病

Courtney D DiNardo1, Harry P Erba2, Sylvie D Freeman3

  • 1Department of Leukemia, UT MD Anderson Cancer Center, Houston, TX, USA.

Lancet (London, England)
|April 17, 2023
PubMed
まとめ

急性骨髄性白血病 (AML) の治療における最近の進歩には,最新の分類と改善された予後ツール,特に測定可能な残留疾患 (MRD) のモニタリングが含まれています. 新しく診断された患者や再発した患者にとって 新しい治療法は より良い結果をもたらします

さらに関連する動画

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

193
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.5K

関連する実験動画

Last Updated: Aug 2, 2025

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.1K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

193
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.5K

科学分野:

  • 血液学
  • 腫瘍学
  • 分子生物学

背景:

  • 急性骨髄性白血病 (AML) の治療は急速に進んでいます.
  • AMLの生物学を理解することで 予後とリスク評価が改善されました
  • 測定可能な残留疾患 (MRD) は,現在,縦断的なリスク評価において重要な役割を果たしています.

研究 の 目的:

  • AML治療の最近の進歩をレビューする.
  • 最新の分類と予測ツールを強調する.
  • AMLの治療法について議論する.

主な方法:

  • 最近の科学文献と臨床試験データをレビューする.
  • 最新の分類システム (WHO,ICC) の分析
  • MRDに対するEuropean LeukemiaNetの勧告と反応の評価

主要な成果:

  • 過去5年間のAML治療における顕著な進展
  • 濃縮化学療法と非濃縮化学療法の両方で改善された結果
  • 再発性AMLに対する新しい標的治療法の開発

結論:

  • AMLの治療環境は変化し 患者の治療結果が改善されています
  • 更新された分類とMRDの評価は患者の管理を洗練します.
  • 治療選択肢の拡大により,AMLの治療能力が向上する.